ArticleBiology direct2026
TRIM71 suppresses cervical cancer progression by inhibiting Nectin4-mediated Wnt/β-catenin signaling.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTripartite motif-containing 71 (TRIM71), an RNA-binding E3 ubiquitin ligase, plays essential roles in malignant progression, but its function in cervical cancer (CC) remains unclear.
methodsTRIM71 expression was assessed in CC cell lines and clinical specimens using qRT-PCR, Western blotting, and immunohistochemistry. The clinical significance of TRIM71 was evaluated through correlation analyses and survival models. Functional assays in vitro and xenograft models in vivo were used to determine the biological roles of TRIM71. RNA-sequencing, RIP-sequencing, luciferase reporter assays, actinomycin D decay assays, and co-immunoprecipitation assays were performed to elucidate underlying mechanisms.
resultsTRIM71 expression was significantly reduced in CC cell lines and tumor tissues, and its low expression correlated with aggressive clinicopathologic features and poorer survival, identifying it as an independent prognostic factor. Functionally, TRIM71 overexpression impaired CC cell proliferation, migration, invasion, and cytoskeletal remodeling, whereas TRIM71 loss enhanced these malignant behaviors. In vivo, TRIM71 suppressed tumor growth, lung metastasis, and angiogenesis. Transcriptome analysis and molecular assays showed that TRIM71 inhibited Wnt/β-catenin signaling and Epithelial-mesenchymal transition (EMT). RIP-seq revealed Nectin4 as a direct TRIM71 target. TRIM71 bound the Nectin4 3'-UTR and reduced its mRNA stability without affecting ubiquitination. Rescue experiments demonstrated that Nectin4 was essential for TRIM71-mediated repression of Wnt/β-catenin signaling, as Nectin4 restoration or pathway activation reversed TRIM71's inhibitory effects, whereas Nectin4 silencing or pathway inhibition negated the impact of TRIM71 knockout.
conclusionsTRIM71 may function as a tumor suppressor in CC by regulating Nectin4 expression and influencing Wnt/β-catenin signaling, EMT, tumor progression, and angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.